Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - emselex
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp0d9fdb5a39ccb7b71c8ef7225226fb5e
identifier: http://ema.europa.eu/identifier
/EU/1/04/294/001-006
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Emselex 7.5 mg prolonged-release tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-0d9fdb5a39ccb7b71c8ef7225226fb5e
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/04/294/001-006
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - emselex
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
How Emselex works Emselex reduces the activity of an overactive bladder. This enables you to wait longer before you go to the toilet and it increases the amount of urine that your bladder can hold.
What Emselex can be used for Emselex belongs to a class of medicines which relax the muscles of the bladder. It is used in adults for the treatment of the symptoms of overactive bladder conditions - such as a sudden urge to rush to the toilet, needing to go to the toilet frequently and/or not getting to the toilet in time and wetting yourself (urge incontinence).
Do not take Emselex:
Warnings and precautions Talk to your doctor before taking Emselex
During treatment with Emselex, tell your doctor straight away and stop taking Emselex if you experience swelling of the face, lips, tongue and/or throat (signs of angioedema).
Children and adolescents
Emselex is not recommended for use in children and adolescents (<18 years).
Other medicines and Emselex Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. This is particularly important if you are taking any of the following as your doctor may need to adjust your dose of Emselex and/or the other medicine:
Emselex with food and drink Eating food has no effect on Emselex. Grapefruit juice may interact with Emselex. Tell your doctor if you are taking grapefruit juice regularly.
Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Emselex is not recommended during pregnancy. Emselex should be taken with caution while breast-feeding.
Driving and using machines Emselex may cause effects such as dizziness, blurred vision, trouble sleeping or drowsiness. If you have any of these symptoms whilst taking Emselex, consult your doctor for advice on changing the dose or considering an alternative treatment. You should not drive or use machines if you are affected by these symptoms. For Emselex, these side effects have been reported to be uncommon (see section 4).
Always take Emselex exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. If you have the impression that the effect of Emselex is too strong or too weak, talk to your doctor or pharmacist.
How much Emselex to take The recommended starting dose, including for patients aged over 65 years, is 7.5 mg daily. Depending on your response to Emselex, your doctor may increase your dose to 15 mg daily, two weeks after starting therapy.
These doses are suitable for people with mild liver problems or people with kidney problems.
Take Emselex tablets once a day with liquid, at about the same time each day.
The tablet may be taken with or without food. Swallow the tablet whole. Do not chew, split or crush it.
If you take more Emselex than you should If you have taken more tablets than you have been told to take, or if someone else accidentally takes your tablets, go to your doctor or hospital for advice immediately. When seeking medical advice, make sure that you take this leaflet and your remaining tablets with you to show them to the doctor. People who have taken an overdose may have dry mouth, constipation, headache, indigestion and nasal dryness. Overdose with Emselex may lead to severe symptoms requiring emergency treatment in hospital.
If you forget to take Emselex If you forget to take Emselex at the usual time, take it as soon as you remember, unless it is the time for your next dose. Do not take a double dose to make up for a forgotten dose.
If you stop taking Emselex Your doctor will tell you how long your treatment with Emselex will last. Do not stop treatment early because you do not see an immediate effect. Your bladder will need some time to adapt. Finish the course of treatment prescribed by your doctor. If you have not noticed any effect by then, discuss it with your doctor.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. The side effects caused by Emselex are usually mild and temporary.
Some side effects could be serious Not known (frequency cannot be estimated from the available data) Serious allergic reactions including swelling, mainly of the face and neck (angioedema).
Other side effects Very common (may affect more than 1 in 10 people) Dry mouth, constipation.
Common (may affect up to 1 in 10 people) Headache, abdominal pain, indigestion, feeling sick, dry eyes, nasal dryness.
Uncommon (may affect up to 1 in 100 people) Fatigue, accidental injury, facial swelling, high blood pressure, diarrhoea, flatulence, ulceration of the mucous membrane of the mouth, increased liver enzymes (this shows abnormal functioning of the liver), swelling including swelling of the hands, ankles or feet, dizziness, sleeplessness, drowsiness, abnormal thinking, runny nose (rhinitis), cough, shortness of breath, dry skin, itching, rash, sweating, visual disturbance including blurred vision, taste disturbance, urinary tract disorder or infection, impotence, discharge and itching in the vagina, bladder pain, inability to empty your bladder.
Not known (frequency cannot be estimated from the available data) Depressed mood/mood alterations, hallucination.
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
What Emselex contains
What Emselex looks like and contents of the pack Emselex 7.5 mg prolonged-release tablets are round, convex white tablets and are debossed with DF
on one side and 7.5 on the other.
The tablets are available in blister packs containing 7, 14, 28, 49, 56 or 98 tablets or in multipacks containing 140 (10x14) tablets. Not all pack sizes may be available in your country.
Marketing Authorisation Holder pharmaand GmbH Taborstrasse 1 1020 Vienna Austria
Manufacturer DREHM Pharma GmbH Gr nbergstrasse 15/3/3 1120 Vienna Austria
This leaflet was last revised in
Other sources of information Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu
Package leaflet: information for the user
Emselex 15 mg prolonged-release tablets Darifenacin
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Entry 1 - fullUrl = Composition/composition-en-0d9fdb5a39ccb7b71c8ef7225226fb5e
Resource Composition:
Generated Narrative: Composition composition-en-0d9fdb5a39ccb7b71c8ef7225226fb5e
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/04/294/001-006status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - emselex
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp0d9fdb5a39ccb7b71c8ef7225226fb5e
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp0d9fdb5a39ccb7b71c8ef7225226fb5e
identifier:
http://ema.europa.eu/identifier
/EU/1/04/294/001-006type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Emselex 7.5 mg prolonged-release tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en